Literature DB >> 132088

Cutaneous reactions to propranolol (Inderal).

H A Jensen, H I Mikkelsen, S Wadskov, J Sondergaard.   

Abstract

Six patients wit psoriasiform cutaneous eruptions that developed during long-term therapy with propranolol (Inderal) have been studied. The cutaneous changes closely resembled those seen during treatment with practolol (Eraldin). The duration of treatment before the rash was recognized averaged 10 months, which is about the same latency period as in patients with practolol-induced exanthemas. The exanthemas disappeared gradually within 1-5 weeks after treatment with propranolol had been stopped. In 4 of 5 patients the skin eruptions reappeared within 2-4 days after oral challenge with propranolol. In the fifth patient, who developed a rash after challenge with practolol and severe abdominal colics after challenge with oxprenolol, no further provocation tests with propranolol were attempted. Skin biopsies obtained from 3 patients showed a microscopical picture similar to that seen in practolol exanthemas. The pathogenetic mechanism responsible for these adverse cutaneous reactions is unknown. However, since the possibility exists, that these changes may be caused by blockade of the epidermal beta-receptors, it is recommended that all patients receiving beta-blocking drugs should be examined carefully for similar adverse reactions. Special attention should be drawn to the reversible skin changes, since during treatment with practolol these have often preceded serious complications from other organs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 132088     DOI: 10.1111/j.0954-6820.1976.tb06749.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  6 in total

1.  Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance.

Authors:  Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2010-01

2.  Psoriasis and psoriasiform eruptions associated with propranolol--the role of an immunological mechanism.

Authors:  S Halevy; E Livni
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

3.  Adverse reactions to practolol in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program.

Authors:  H J Pfeifer; D J Greenblatt; J Koch-Weser
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

Review 4.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

5.  Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes.

Authors:  E Duzman; N Rosen; M Lazar
Journal:  Br J Ophthalmol       Date:  1983-10       Impact factor: 4.638

Review 6.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.